Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPujals-Pruneda, Mireia
dc.contributor.authorResar, Linda
dc.contributor.authorVillanueva Cardús, Josep
dc.date.accessioned2022-06-16T06:39:54Z
dc.date.available2022-06-16T06:39:54Z
dc.date.issued2021-09-09
dc.identifier.citationPujals M, Resar L, Villanueva J. HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location! Biomolecules. 2021 Sep 9;11(9):1334.
dc.identifier.issn2218-273X
dc.identifier.urihttps://hdl.handle.net/11351/7695
dc.descriptionHMGA1; Secretome; Unconventional protein secretion
dc.description.abstractThe gene encoding the High Mobility Group A1 (HMGA1) chromatin remodeling protein is upregulated in diverse cancers where high levels portend adverse clinical outcomes. Until recently, HMGA1 was assumed to be a nuclear protein exerting its role in cancer by transcriptionally modulating gene expression and downstream signaling pathways. However, the discovery of an extracellular HMGA1-RAGE autocrine loop in invasive triple-negative breast cancer (TNBC) cell lines implicates HMGA1 as a “moonlighting protein” with different functions depending upon cellular location. Here, we review the role of HMGA1, not only as a chromatin regulator in cancer and stem cells, but also as a potential secreted factor that drives tumor progression. Prior work found that HMGA1 is secreted from TNBC cell lines where it signals through the receptor for advanced glycation end products (RAGE) to foster phenotypes involved in tumor invasion and metastatic progression. Studies in primary TNBC tumors also suggest that HMGA1 secretion associates with distant metastasis in TNBC. Given the therapeutic potential to target extracellular proteins, further work to confirm this role in other contexts is warranted. Indeed, crosstalk between nuclear and secreted HMGA1 could change our understanding of tumor development and reveal novel therapeutic opportunities relevant to diverse human cancers overexpressing HMGA1.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesBiomolecules;11(9)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectOncogens
dc.subjectCàncer
dc.subject.meshNeoplasms
dc.subject.meshHMGA1a Protein
dc.subject.mesh/metabolism
dc.subject.meshOncogenes
dc.titleHMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location!
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/biom11091334
dc.subject.decsneoplasias
dc.subject.decsproteína HMGA1a
dc.subject.decs/metabolismo
dc.subject.decsoncogenes
dc.relation.publishversionhttps://doi.org/10.3390/biom11091334
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Pujals M] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Resar L] Department of Medicine, Division of Hematology, The Johns Hopkins University School of Medicine, Baltimore, USA. Departments of Medicine (Hematology), Oncology, Pathology and Institute of Cellular Engineering, The Johns Hopkins University School of Medicine, Baltimore, USA. Pathobiology, Cellular and Molecular Medicine and Human Genetics Graduate Programs, The Johns Hopkins University School of Medicine, Baltimore, USA. [Villanueva J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
dc.identifier.pmid34572547
dc.identifier.wos000699120800001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F01292
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record